LONDON--(BUSINESS WIRE)--Infiniti Research, a leading market intelligence solutions provider, has recently announced the completion of its latest success story on market identification solution. This success story highlights how the experts at Infiniti Research helped an orphan drugs market client tackle manufacturing hurdles, identify profitable markets for product launch, and achieve huge commercial success for its newly developed orphan drug.
The demand for orphan drugs is expected to significantly increase over the coming years owing to the surge in the prevalence of rare diseases and favorable government policies. In addition to this, increase in R&D and drug development are expected to propel the orphan drugs market growth. However, orphan drugs present numerous development and manufacturing challenges. Also, recent studies indicate that more than half of the orphan drugs took around 18% longer on average to go from first patent filing to product launch in comparison to all other new drugs. As such, orphan drugs manufacturers need to stay prepared to manage the risks associated with orphan drug development and manufacturing.
Orphan drugs present a number of unique challenges for pharma companies looking to commercialize their products in the US. Our market identification solutions can help you to identify niche markets for your product launch and achieve huge profitability. Request a free proposal today.
The Business Challenge:
An orphan drugs manufacturing firm, based out of Central Europe, was looking to develop and launch a new orphan drug in the US. To gain data-driven insights and identify the niche markets for their product launch, they wanted to gather comprehensive insights into the market developments, technology’s adoption trends, and patent landscape. Also, the client faced difficulties in finding patients who meet their inclusion criteria to enroll in clinical trials. The client also needed help in pre-launch preparations and supply chain development. In addition, the client wanted to develop a sound marketing strategy for their new orphan drugs. They chose to partner with Infiniti Research to leverage their expertise in offering market identification solution.
Collaborating to find patients for trials, improving diagnosis, demonstrating value, engaging with caregivers and developing specialized supply chains are just some of the factors to consider for successful commercialization of your new orphan drugs. We can help you achieve all these strategic objectives. Contact us today.
The Solution Offered:
To help the client tackle the above-mentioned challenges and efficiently commercialize its new orphan drug, the experts at Infiniti Research used a combination of technology assessment, sales intelligence, market potential, marketing strategy, and market forecast study. The engagement also involved conducting patient recruitment for finding patients for clinical trials, establishing demo campaigns to test the effectiveness, and evaluating supply chain complexities.
Infiniti’s market identification solution helped the client to:
- Get the Food and Drug Administration (FDA) approvals in six months
- Identify smaller regions in the United States to target the new orphan drug
- Adapt Quality-by-design (QbD) and design of experiment (DoE) approaches
- Accelerate drug development and reduce costs
- Recruit patients for clinical trials
- Devise sound sales and marketing tactics
- Drive payers engagement and increase sales
- Achieve huge commercial success for its new orphan drugs
Want to gather detailed insights into this engagement? Request more info and our experts will get in touch with you with relevant insights.
About Infiniti Research
Established in 2003, Infiniti Research, is a leading market intelligence company providing smart solutions to address your business challenges. Infiniti Research studies markets in more than 100 countries to help analyze competitive activity, see beyond market disruptions, and develop intelligent business strategies. To know more, visit: https://www.infinitiresearch.com/about-us
